Paul Matteis Recent News
Pros And Cons Of All The News Out Of Acadia Pharma This Week
Neurocrine's Phase 2 Disappointment: Why The Company's Down, But Not Out
Spinraza Wins 'Best Case Approval'; Leerink Raises Targets On Biogen, Ionis
Leerink Rates Zogenix Outperform Ahead Of AES Meeting
GW Pharma Rapidly Approaching CNS Launch; Leerink Starts Coverage With $162 Target
Leerink Downgrades Orexigen, Cuts Target From $4.50 To $2
Does Oncomed Pharma Have Any Upside Left?
Ovascience Has Lack Of Visibility And 'Sluggish' Uptake, Warns Leerink
Leerink: Time To Buy Nabriva Therapeutics' 'Unique Differentiation'
Leerink: Europe Deal Coming For Orexigen Therapeutics
Leerink Comments On Orexigen Therapeutics, Says Current Projections Could Prove To Be 'Conservative'